Lyell Immunopharma, Inc. — Director's Dealing 2021

Jun 23, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2021-06-21

Reporting Person: NELSEN ROBERT (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-21	Common Stock	C	18206358	—	Acquired	18206358	Indirect
2021-06-21	Common Stock	C	18206358	—	Acquired	18206358	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-21	Series A Convertible Preferred Stock	$	C	17771216	Disposed		Common Stock (17771216)	Indirect
2021-06-21	Series A Convertible Preferred Stock	$	C	17771216	Disposed		Common Stock (17771216)	Indirect
2021-06-21	Series C Convertible Preferred Stock	$	C	435142	Disposed		Common Stock (435142)	Indirect
2021-06-21	Series C Convertible Preferred Stock	$	C	435142	Disposed		Common Stock (435142)	Indirect

Footnotes

F1: The Issuer's Series A Convertible Preferred Stock and Series C Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date.

F2: These shares are directly held by ARCH Venture Fund IX, L.P. (ARCH IX). ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general
partner of ARCH IX.

F3: ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. The Reporting Person
is a managing director of AVP IX LLC ("AVP IX MD"). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held
by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX
Overage, and the AVP IX MD may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX
Overage. AVP IX LP, AVP IX Overage LP and AVP IX LLC each disclaim beneficial ownership except to the extent of any pecuniary interest
therein.

F4: The Reporting Person is an AVP IX MD and may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage. The
Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any.

F5: These shares are directly held by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage). ARCH Venture Partners IX Overage, L.P. (AVP IX
Overage LP) is the sole general partner of ARCH IX Overage.